Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes

Blood

Volumn 108, Issue 9, 2006, Pages 3161-3167

  Hill, Deirdre A ^a   Wang, Sophia S ^b   Cerhan, James R ^b   Davis, Scott ^b   Cozen, Wendy ^b   Severson, Richard K ^b   Hartge, Patricia ^b   Wacholder, Sholom ^b   Yeager, Meredith ^b   Chanock, Stephen J ^b   Rothman, Nathaniel ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIBRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P53; RAG1 PROTEIN; RECOMBINASE; WERNER SYNDROME PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA REPAIR; EXCISION REPAIR; FEMALE; GENE; GENE DOSAGE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POPULATION STRUCTURE; PRIORITY JOURNAL; RAD23 HOMOLOG B GENE; UNITED STATES; X RAY REPAIR CROSS COMPLEMENTING 2 GENE; X RAY REPAIR CROSS COMPLEMENTING 3 GENE; X RAY REPAIR CROSS COMPLEMENTING 4 GENE; X RAY REPAIR CROSS COMPLEMENTING 5 GENE; XERODERMA PIGMENTOSUM C GENE;

EID: 33751193888     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-01-026690     Document Type: Article

References (43)

1. Fan YS, Rizkalla K. Comprehensive cytogenetic analysis including multicolor spectral karyotyping and interphase fluorescence in-situ hybridization in lymphoma diagnosis: a summary of 154 cases. Cancer Genet Cytogenet. 2003;143:73-79.
2. Yano T, van Krieken JH, Magrath IT, Longo DL, Jaffe ES, Raffeld M. Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood. 1992;79:1282-1290.
3. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature. 1985;315:340-343.
4. Jager U, Bocskor S, Le T, et al. Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14; 18) translocation. Blood. 2000;95:3520-3529.
5. Papavasiliou FN, Schatz DG. Cell-cycle-regulated DNA double-stranded breaks in somatic hypermutation of immunoglobulin genes. Nature. 2000;408:216-221.
6. Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood. 1990;75:1848-1852.
7. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346.
8. Hiom K, Melek M, Gellert M. DNAtransposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 1998;94:463-470.
9. Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000;404:897-900.
10. Difilippantonio MJ, Petersen S, Chen HT, et al. Evidence for replicative repair of DNAdouble-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med. 2002;196:469-480.
11. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 2001;97:81-88.
12. Moshous D, Pannetier C, de Chasseval R, et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest. 2003;111:381-387.
13. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. 2000;405:697-700.
14. German J, Ellis NA. Bloom syndrome. In: Vogelstein B, Kinzler K, eds. The Genetic Basis of Human Cancers. New York, NY:McGraw-Hill; 1998:301-315.
15. Auerbach AD, Buchwald M, Joenje H. Fanconi anemia. In: Vogelstein B, Kinzler K, eds. The Genetic Basis of Human Cancers. New York, NY: McGraw-Hill; 1998:317-332.
16. International Nijmegen Breakage Syndrome Study Group. Nijmegen breakage syndrome. Arch Dis Child. 2000;82:400-406.
17. Morrison C, Smith GC, Stingl L, et al.Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. NatGenet. 1997;17:479-482.
18. Akbari M, Otterlei M, Pena-Diaz J, et al. Repair of U/G and U/A in DNAby UNG2-associated repair complexes takes place predominantly by short-patch repair both in proliferating and growth-arrested cells. Nucleic Acids Res. 2004;32:5486-5498.
19. Smedby KE, Hjalgrim H, Melbye M, et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst. 2005;97:199-209.
20. Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ. 1995;310:1491-1495.
21. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNArepair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797.
22. Esteller M, Gaidano G, Goodman SN, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94:26-32.
23. Chatterjee N, Hartge P, Cerhan JR, et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev. 2004;13:1415-1421.
24. Packer BR, Yeager M, Burdett L, et al. Cancer-SNPs (formerly known as SNP500Cancer): a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 2006;34:D617-D621.
25. National Cancer Institute. Cancer Genome Anatomy Project SNP500Cancer Database. Available at: http://snp500cancer.nci.nih.gov. Accessed September 23, 2004.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
27. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434-442.
28. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7:27-38.
29. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-872.
30. Fred Hutchinson Cancer Research Center. Blocks WWW Server. Available at: http://blocks.fhcrc.org/sift/SIFT.html. Accessed April 12, 2005.
31. Corneo B, Moshous D, Gungor T, et al. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 2001;97:2772-2776.
32. Girard PM, Kysela B, Harer CJ, Doherty AJ, Jeggo PA. Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of two linked polymorphisms. Hum Mol Genet. 2004;13:2369-2376.
33. Roddam PL, Rollinson S, O'Driscoll M, Jeggo PA, Jack A, Morgan GJ. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour _haracterized by aberrant class switch recombination. J Med Genet. 2002;39:900-905.
34. Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362-364.
35. Spurdle AB, Hopper JL, Chen X, et al. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev. 2002;11:413-416.
36. Auranen A, Spurdle AB, Chen X, et al. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int J Cancer. 2003;103:427-430.
37. Wenham RM, Schildkraut JM, McLean K, et al. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003;9:4396-4403.
38. Cox DG, Hankinson SE, Hunter DJ. No association between BRCA2 N372H and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:1353-1354.
39. The Breast Cancer Linkage Consortium. Cancer Risks in BRCA2 Mutation Carriers. J Natl Cancer Inst. 1999;91:1310-1316.
40. Goto M, Miller RW, Ishikawa Y. Sugano H. Excess of rare cancers in Werner syndrome. Cancer Epidemiol Biomarkers Prev. 1996;5:239-246.
41. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:359-365.
42. Nelson HH, Kelsey KT, Mott LA, Karagas MR. The XRCC1Arg399Gln polymorphism, sunburn, and nonmelanoma skin cancer: evidence of gene-environment interaction. Cancer Res. 2002;62:152-155.
43. Smedby KE, Lindgren CM, Hjalgrim H, et al. Variation in DNArepair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev. 2006;15:258-265.